Cite
HARVARD Citation
Wong, N. et al. (2016). Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD).. Atherosclerosis. pp. e245-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Wong, N. et al. (2016). Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD).. Atherosclerosis. pp. e245-. [Online].